Skip to main content
SpringerLink
Log in

More scope for ACE inhibitor use in left ventricular systolic dysfunction

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 28: 1323–7

    Article  PubMed  CAS  Google Scholar 

  2. Konstam MA, Dracup K, Baker D, et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Clinical practice guideline No. 11. Agency for Health Care Policy and Research: Rockville, Md, 1994. AHCPR Publication No. 94-0612

    Google Scholar 

  3. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. PharmacoEconomics 1996 Mar; 9(3): 188–97

    Article  PubMed  CAS  Google Scholar 

  4. O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13: S107–12

    PubMed  Google Scholar 

  5. Elixhauser A, McCarthy E. Clinical classifications for health policy research, version 2: hospital inpatient statistics. [Monograph online]. Agency for Health Care Policy and Research: Rockville, Md, 1996; AHCPR Publication No. 96-0017. Available from: URL: http://www.access.gpo.gov/ahcpr/hcuprnl.html [Accessed 97/05/15]

    Google Scholar 

  6. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997 May; 18: 736–53

    Article  Google Scholar 

  7. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6

    Article  PubMed  CAS  Google Scholar 

  8. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med 1997; 157: 1103–8

    Article  Google Scholar 

  9. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on angiotensin-converting-enzyme inhibitors in patients with left ventricular dysfunction. Am J Health-Syst Pharm 1997; 54: 299–313

    Google Scholar 

  10. Williams, JF Jr, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995; 92: 2764–84

    Article  Google Scholar 

  11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35

    Article  Google Scholar 

  12. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10

    Article  PubMed  CAS  Google Scholar 

  13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302

    Article  Google Scholar 

  14. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91

    Article  Google Scholar 

  15. PDR Generics. 3rd ed. Montvale, NJ: Medical Economics, 1997

  16. The earlier and more widespread use of ACE inhibitors in CHF is likely to be cost effective. Drug Ther Perspect 1996 Jul 8; 8(1): 14–5

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

More scope for ACE inhibitor use in left ventricular systolic dysfunction. Drugs Ther. Perspect 10, 5–8 (1997). https://doi.org/10.2165/00042310-199710110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199710110-00002

Keywords

Search

Navigation